Boryung is a pharmaceutical company that has established a strong foundation in drug development, particularly highlighted by the successful creation of 'Kanarb', the first domestic hypertension drug in South Korea. The company has demonstrated its comprehensive capabilities by independently managing all stages of drug development, including candidate material excavation, raw material synthesis, formulation research, and conducting clinical trials. Boryung is actively expanding its research efforts into various therapeutic areas, focusing on the development of drugs for cancer treatment, antibiotics, new chemical entities (NCEs), gene therapy, and biopharmaceuticals. 

A significant aspect of Boryung's pipeline is the 'Kanarb Value-up Pipeline', which aims to enhance the treatment of hypertension in patients with associated metabolic diseases. This pipeline includes new chemical entities and investigational medicinal products (IMDs) that are developed in-house, with the goal of increasing market competitiveness and global reach. Boryung's commitment to research and development is evident in its diverse pipeline, which encompasses treatments for various conditions, including cancer, chronic kidney disease, and diabetes, showcasing the company's dedication to addressing major health challenges through innovative pharmaceutical solutions.

South Korea

Boryung is a healthcare investment company founded in 1957 and headquartered in Seoul, South Korea. Following the company’s mission to become an indispensable contributor to human health, we have expanded our business portfolio to the space healthcare industry.

Recognizing space as a new growth realm, we acknowledge the increasing number of individuals anticipated to embark on extended space missions, highlighting the importance of ensuring human survival in the hostile space environment. Hence, Boryung believes there will be substantial opportunities to foster new technologies and meet the emerging needs in this field.

Boryung

Company Details